In the latter trial, in cohort 1, patients with advanced HER2-overexpressing breast cancer receive zanidatamab plus chemotherapy while in cohort 2, patients with advanced HER2-overexpressing gastric/esophageal cancer receive zanidatamab plus chemotherapy and tislelizumab [77]. This evidence concerns the gene ERBB2 and breast carcinoma.